<p>雅培（NYSE:ABT - 获取免费报告）股票在周四创下 52 周新高。该公司交易价格最高达到 132.85 美元，最后交易价格为 132.92 美元，成交量为 547305 股。该股票此前收盘价为 132.13 美元。</p>
<p>获取 <strong>雅培</strong> 的提醒：</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>雅培将在 2025 年超越医疗保健股票</li>
</ul>
<p>ABT 一直是多份分析师报告的主题。巴克莱在 1 月 27 日的研究报告中重申了 “增持” 评级，并将雅培的目标价从 149.00 美元上调至 158.00 美元。富国银行在 1 月 23 日的研究报告中将雅培的目标价从 133.00 美元上调至 136.00 美元，并给予该股票 “增持” 评级。StockNews.com 在 2 月 12 日的研究报告中将雅培的评级从 “强力买入” 下调至 “买入”。Evercore ISI 在 1 月 2 日的研究报告中将雅培的目标价上调至 136.00 美元，并给予该股票 “买入” 评级。最后，斯蒂费尔·尼古拉斯在 1 月 23 日的报告中将雅培的目标价从 130.00 美元上调至 135.00 美元，并给予公司 “买入” 评级。四位股票研究分析师对该股票给予持有评级，十四位给予买入评级，一位给予强力买入评级。根据 MarketBeat.com 的数据，雅培目前的平均评级为 “适度买入”，平均目标价为 133.06 美元。</p>
<p><strong>阅读我们关于 ABT 的最新报告</strong></p>
<h2>雅培股票上涨 0.4%</h2>
<ul>
<li>这些是适合长期投资的顶级健康股票</li>
</ul>
<p>该公司的市值为 2301.9 亿美元，市盈率为 17.35，PEG 比率为 2.43，贝塔值为 0.75。该公司的速动比率为 1.14，流动比率为 1.60，债务股本比率为 0.32。该业务的 50 日移动平均价格为 119.93 美元，200 日移动平均价格为 116.53 美元。</p>
<p>雅培（NYSE:ABT - 获取免费报告）最近于 1 月 22 日发布了季度财报。这家医疗产品制造商报告该季度每股收益（EPS）为 1.34 美元，符合分析师的共识预期 1.34 美元。雅培的股本回报率为 20.74%，净利润率为 31.95%。该业务的季度收入为 109.7 亿美元，而分析师预期为 110.3 亿美元。在去年同期，该业务的每股收益为 1.19 美元。雅培的季度收入同比增长 7.2%。分析师预计雅培在当前年度的每股收益将达到 5.14 美元。</p>
<h2>雅培增加股息</h2>
<ul>
<li>MarketBeat 周回顾 – 10/14 - 10/18</li>
</ul>
<p>该公司最近宣布了一项季度股息，已于 2 月 14 日支付。1 月 15 日的股东获得了 0.59 美元的股息。这相当于年化股息 2.36 美元，收益率为 1.78%。这比雅培之前的季度股息 0.55 美元有所增加。除息日期为 1 月 15 日。雅培的股息支付比率为 30.85%。</p>
<h2>雅培的内部买卖</h2>
<p>在其他雅培的新闻中，执行副总裁 Daniel Gesua Sive Salvadori 于 1 月 30 日以 128.50 美元的平均价格出售了 23771 股公司的股票，总价值为 3054573.50 美元。交易后，该执行副总裁现在持有 125697 股公司股票，价值约为 16152064.50 美元。此次交易使其持股减少了 15.90%。该交易已在向证券交易委员会提交的文件中披露，可以通过此链接访问。公司内部人士持有公司股票的 1.10%。</p>
<h2>对雅培的对冲基金观点</h2>
<p>一些机构投资者和对冲基金最近买卖了 ABT 的股票。Allspring Global Investments Holdings LLC 在第三季度将其在雅培的股份增加了 17.9%。Allspring Global Investments Holdings LLC 目前持有 268538 股雅培的股票，价值 30616000 美元，此前在该期间内又收购了 40783 股。Trilogy Capital Inc.在第三季度将其在雅培的持股增加了 5.6%。Trilogy Capital Inc.目前持有 2503 股雅培的股票，价值 285000 美元，此前在上个季度又购买了 132 股。Copeland Capital Management LLC 在第三季度以约 142000 美元的价格购买了雅培的新股份。My Legacy Advisors LLC 在第三季度将其在雅培的持股增加了 2.3%。My Legacy Advisors LLC 目前持有 4180 股雅培的股票，价值 477000 美元，此前在上个季度又购买了 92 股。最后，Symphony Financial Ltd. Co.在第三季度将其在雅培的持股增加了 11.2%。Symphony Financial Ltd. Co.目前持有 8571 股雅培的股票，价值 964000 美元，此前在上个季度又购买了 863 股。机构投资者和对冲基金持有公司 75.18% 的股票。</p>
<h2>关于雅培</h2>
<p>（获取免费报告）</p>
<p>雅培（Abbott Laboratories）及其子公司在全球范围内发现、开发、制造和销售医疗保健产品。它分为四个业务部门：成熟药品、诊断产品、营养产品和医疗器械。该公司提供用于治疗胰腺外分泌功能不全、肠易激综合症或胆道痉挛、肝内胆汁淤积或抑郁症状、妇科疾病、激素替代疗法、血脂异常、高血压、甲状腺功能减退、梅尼埃病和前庭性眩晕、疼痛、发热、炎症和偏头痛的仿制药，以及提供抗感染药物克拉霉素、流感疫苗和调节结肠生理节律的产品。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过雅培（Abbott Laboratories）</li>
<li>如何绘制斐波那契价格拐点水平</li>
<li>沃尔玛面临关税压力，消费者趋势依然积极</li>
<li>超买股票解析：你应该交易它们吗？</li>
<li>特斯拉：买入的两个理由，卖出的一个理由</li>
<li>纳斯达克是什么？完整概述及历史</li>
<li>你应该长期持有 NVIDIA 股票还是交易它？</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在雅培（Abbott Laboratories）吗？</h2>
<p>在你考虑雅培（Abbott Laboratories）之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而雅培（Abbott Laboratories）并不在名单上。</p>
<p>虽然雅培（Abbott Laboratories）目前在分析师中获得了 “适度买入” 的评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

雅培

<p>雅培（Abbott Laboratories，NYSE:ABT）股票达到 52 周新高 132.92 美元，交易量为 547,305 股。分析师对该股票的平均评级为 “适度买入”，目标价为 133.06 美元。公司报告上个季度每股收益为 1.34 美元，符合预期，并宣布季度股息增加至 0.59 美元。内部交易活动包括执行副总裁 Daniel Gesua Sive Salvadori 出售 23,771 股。机构投资者最近也增加了对公司的持股</p>

<p>Abbott Laboratories (NYSE:ABT - Get Free Report) shares hit a new 52-week high on Thursday . The company traded as high as $132.85 and last traded at $132.92, with a volume of 547305 shares. The stock had previously closed at $132.13.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 获取免费报告）股票在周四创下 52 周新高。该公司交易价格最高达到 132.85 美元，最后交易价格为 132.92 美元，成交量为 547305 股。该股票此前收盘价为 132.13 美元。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>雅培</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>Abbott Laboratories Will Outperform Healthcare Stocks in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>雅培将在 2025 年超越医疗保健股票</li>
</ul>
</div><p>ABT has been the topic of a number of analyst reports. Barclays reissued an &#34;overweight&#34; rating and issued a $158.00 price target (up previously from $149.00) on shares of Abbott Laboratories in a research note on Monday, January 27th. Wells Fargo &amp; Company raised their price objective on Abbott Laboratories from $133.00 to $136.00 and gave the stock an &#34;overweight&#34; rating in a research report on Thursday, January 23rd. StockNews.com lowered Abbott Laboratories from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research report on Wednesday, February 12th. Evercore ISI raised their price objective on Abbott Laboratories to $136.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, January 2nd. Finally, Stifel Nicolaus lifted their price target on Abbott Laboratories from $130.00 to $135.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, January 23rd. Four equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Abbott Laboratories presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $133.06.</p>
<div class="lb-trans"><p>ABT 一直是多份分析师报告的主题。巴克莱在 1 月 27 日的研究报告中重申了 “增持” 评级，并将雅培的目标价从 149.00 美元上调至 158.00 美元。富国银行在 1 月 23 日的研究报告中将雅培的目标价从 133.00 美元上调至 136.00 美元，并给予该股票 “增持” 评级。StockNews.com 在 2 月 12 日的研究报告中将雅培的评级从 “强力买入” 下调至 “买入”。Evercore ISI 在 1 月 2 日的研究报告中将雅培的目标价上调至 136.00 美元，并给予该股票 “买入” 评级。最后，斯蒂费尔·尼古拉斯在 1 月 23 日的报告中将雅培的目标价从 130.00 美元上调至 135.00 美元，并给予公司 “买入” 评级。四位股票研究分析师对该股票给予持有评级，十四位给予买入评级，一位给予强力买入评级。根据 MarketBeat.com 的数据，雅培目前的平均评级为 “适度买入”，平均目标价为 133.06 美元。</p>
</div><p><strong>Read Our Latest Report on ABT</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 ABT 的最新报告</strong></p>
</div><h2>Abbott Laboratories Trading Up 0.4 %</h2>
<div class="lb-trans"><h2>雅培股票上涨 0.4%</h2>
</div><ul>
<li>These Are The Top Health Stocks to Own for Buy-and-Hold Investing</li>
</ul>
<div class="lb-trans"><ul>
<li>这些是适合长期投资的顶级健康股票</li>
</ul>
</div><p>The firm has a market capitalization of $230.19 billion, a P/E ratio of 17.35, a PEG ratio of 2.43 and a beta of 0.75. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32. The business has a 50-day moving average price of $119.93 and a 200-day moving average price of $116.53.</p>
<div class="lb-trans"><p>该公司的市值为 2301.9 亿美元，市盈率为 17.35，PEG 比率为 2.43，贝塔值为 0.75。该公司的速动比率为 1.14，流动比率为 1.60，债务股本比率为 0.32。该业务的 50 日移动平均价格为 119.93 美元，200 日移动平均价格为 116.53 美元。</p>
</div><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.34. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The business had revenue of $10.97 billion for the quarter, compared to analysts' expectations of $11.03 billion. During the same period in the previous year, the business posted $1.19 earnings per share. Abbott Laboratories's quarterly revenue was up 7.2% on a year-over-year basis. Analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 获取免费报告）最近于 1 月 22 日发布了季度财报。这家医疗产品制造商报告该季度每股收益（EPS）为 1.34 美元，符合分析师的共识预期 1.34 美元。雅培的股本回报率为 20.74%，净利润率为 31.95%。该业务的季度收入为 109.7 亿美元，而分析师预期为 110.3 亿美元。在去年同期，该业务的每股收益为 1.19 美元。雅培的季度收入同比增长 7.2%。分析师预计雅培在当前年度的每股收益将达到 5.14 美元。</p>
</div><h2>Abbott Laboratories Increases Dividend</h2>
<div class="lb-trans"><h2>雅培增加股息</h2>
</div><ul>
<li>MarketBeat Week in Review – 10/14 - 10/18</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 10/14 - 10/18</li>
</ul>
</div><p>The business also recently declared a quarterly dividend, which was paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th were given a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a yield of 1.78%. This is a boost from Abbott Laboratories's previous quarterly dividend of $0.55. The ex-dividend date was Wednesday, January 15th. Abbott Laboratories's dividend payout ratio is 30.85%.</p>
<div class="lb-trans"><p>该公司最近宣布了一项季度股息，已于 2 月 14 日支付。1 月 15 日的股东获得了 0.59 美元的股息。这相当于年化股息 2.36 美元，收益率为 1.78%。这比雅培之前的季度股息 0.55 美元有所增加。除息日期为 1 月 15 日。雅培的股息支付比率为 30.85%。</p>
</div><h2>Insider Buying and Selling at Abbott Laboratories</h2>
<div class="lb-trans"><h2>雅培的内部买卖</h2>
</div><p>In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the business's stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $128.50, for a total value of $3,054,573.50. Following the transaction, the executive vice president now owns 125,697 shares of the company's stock, valued at approximately $16,152,064.50. The trade was a 15.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他雅培的新闻中，执行副总裁 Daniel Gesua Sive Salvadori 于 1 月 30 日以 128.50 美元的平均价格出售了 23771 股公司的股票，总价值为 3054573.50 美元。交易后，该执行副总裁现在持有 125697 股公司股票，价值约为 16152064.50 美元。此次交易使其持股减少了 15.90%。该交易已在向证券交易委员会提交的文件中披露，可以通过此链接访问。公司内部人士持有公司股票的 1.10%。</p>
</div><h2>Hedge Funds Weigh In On Abbott Laboratories</h2>
<div class="lb-trans"><h2>对雅培的对冲基金观点</h2>
</div><p>A number of institutional investors and hedge funds have recently bought and sold shares of ABT. Allspring Global Investments Holdings LLC lifted its stake in shares of Abbott Laboratories by 17.9% during the third quarter. Allspring Global Investments Holdings LLC now owns 268,538 shares of the healthcare product maker's stock valued at $30,616,000 after acquiring an additional 40,783 shares during the period. Trilogy Capital Inc. increased its holdings in Abbott Laboratories by 5.6% in the third quarter. Trilogy Capital Inc. now owns 2,503 shares of the healthcare product maker's stock valued at $285,000 after purchasing an additional 132 shares during the last quarter. Copeland Capital Management LLC bought a new stake in Abbott Laboratories in the third quarter valued at about $142,000. My Legacy Advisors LLC increased its holdings in Abbott Laboratories by 2.3% in the third quarter. My Legacy Advisors LLC now owns 4,180 shares of the healthcare product maker's stock valued at $477,000 after purchasing an additional 92 shares during the last quarter. Finally, Symphony Financial Ltd. Co. increased its holdings in Abbott Laboratories by 11.2% in the third quarter. Symphony Financial Ltd. Co. now owns 8,571 shares of the healthcare product maker's stock valued at $964,000 after purchasing an additional 863 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company's stock.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近买卖了 ABT 的股票。Allspring Global Investments Holdings LLC 在第三季度将其在雅培的股份增加了 17.9%。Allspring Global Investments Holdings LLC 目前持有 268538 股雅培的股票，价值 30616000 美元，此前在该期间内又收购了 40783 股。Trilogy Capital Inc.在第三季度将其在雅培的持股增加了 5.6%。Trilogy Capital Inc.目前持有 2503 股雅培的股票，价值 285000 美元，此前在上个季度又购买了 132 股。Copeland Capital Management LLC 在第三季度以约 142000 美元的价格购买了雅培的新股份。My Legacy Advisors LLC 在第三季度将其在雅培的持股增加了 2.3%。My Legacy Advisors LLC 目前持有 4180 股雅培的股票，价值 477000 美元，此前在上个季度又购买了 92 股。最后，Symphony Financial Ltd. Co.在第三季度将其在雅培的持股增加了 11.2%。Symphony Financial Ltd. Co.目前持有 8571 股雅培的股票，价值 964000 美元，此前在上个季度又购买了 863 股。机构投资者和对冲基金持有公司 75.18% 的股票。</p>
</div><h2>About Abbott Laboratories</h2>
<div class="lb-trans"><h2>关于雅培</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.</p>
<div class="lb-trans"><p>雅培（Abbott Laboratories）及其子公司在全球范围内发现、开发、制造和销售医疗保健产品。它分为四个业务部门：成熟药品、诊断产品、营养产品和医疗器械。该公司提供用于治疗胰腺外分泌功能不全、肠易激综合症或胆道痉挛、肝内胆汁淤积或抑郁症状、妇科疾病、激素替代疗法、血脂异常、高血压、甲状腺功能减退、梅尼埃病和前庭性眩晕、疼痛、发热、炎症和偏头痛的仿制药，以及提供抗感染药物克拉霉素、流感疫苗和调节结肠生理节律的产品。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Abbott Laboratories</li>
<li>How to Plot Fibonacci Price Inflection Levels</li>
<li>Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive</li>
<li>Overbought Stocks Explained: Should You Trade Them?</li>
<li>Tesla: 2 Reasons to Buy, 1 Reason to Run</li>
<li>What is the Nasdaq? Complete Overview with History</li>
<li>Should You Hold NVIDIA Stock for the Long Haul or Trade It?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过雅培（Abbott Laboratories）</li>
<li>如何绘制斐波那契价格拐点水平</li>
<li>沃尔玛面临关税压力，消费者趋势依然积极</li>
<li>超买股票解析：你应该交易它们吗？</li>
<li>特斯拉：买入的两个理由，卖出的一个理由</li>
<li>纳斯达克是什么？完整概述及历史</li>
<li>你应该长期持有 NVIDIA 股票还是交易它？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在雅培（Abbott Laboratories）吗？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑雅培（Abbott Laboratories）之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而雅培（Abbott Laboratories）并不在名单上。</p>
</div><p>While Abbott Laboratories currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然雅培（Abbott Laboratories）目前在分析师中获得了 “适度买入” 的评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

雅培实验室（纽约证券交易所代码：ABT）创下 52 周新高 - 原因如下